In this study, we aim to investigate the mutation features of DDR genes, to reveal their associations with clinical characteristics, biomarker, response, and prognosis in advanced NSCLC patients without EGFR and ALK alterations who received platinum-based chemotherapy and platinum-based chemotherapy/immunotherapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.